Tiziana to Host Investor Call to Discuss Exclusive License Agreement to Evaluate Foralumab, a Novel, Fully Human Anti-CD3 Monoclonal Antibody, in Conjunction with Allogeneic CAR T Candidates for Cancer Treatment
07 Setembro 2021 - 3:00AM
Tiziana Life Sciences plc (NASDAQ: TLSA, LSE: TILS) ("Tiziana" or
the "Company"), a biotechnology company focused on innovative
therapeutics for oncology, inflammation, and infectious
diseases,
will host a conference call and
audio webcast on Wednesday, September 8, at 4:15 p.m. ET to discuss
its recently announced exclusive license agreement to evaluate
Foralumab, the Company’s novel, fully human anti-CD3 monoclonal
antibody, in conjunction with allogenic CAR T candidates for cancer
treatment.
Date: |
Wednesday, September 8, 2021 |
|
|
Time: |
4:15 p.m. Eastern Time |
|
|
Live Call: |
+1-877-407-9716 (U.S. Toll-Free) or +1-201-493-6779
(International) |
|
|
Webcast: |
http://public.viavid.com/index.php?id=146493 |
For interested individuals unable to join the
conference call, a dial-in replay of the call will be available
until September 22, 2021 and can be accessed by dialing
+1-844-512-2921 (U.S. Toll Free) or +1-412-317-6671 (International)
and entering replay pin number: 13722965.
About Foralumab
Foralumab (TZLS-401, formerly NI-0401), the only
entirely human anti-CD3 mAb, shows reduced release of cytokines as
compared to other anti-CD3 mAbs after IV administration in patients
with Crohn's disease with decreases in the classic side effects of
cytokine release syndrome and improves the overall safety profile
of Foralumab. In a humanized mouse model (NOD/SCID IL2γc-/-), it
was shown that while targeting the T cell receptor, orally
administered Foralumab modulates immune responses of the T cells,
enhances regulatory T-cells (Tregs) and thus provides therapeutic
benefit in treating inflammatory and autoimmune diseases without
the occurrence of potential adverse events usually associated with
parenteral mAb therapy (Ogura M. et al., 2017 Clin Immunol 183,
240-246). Based on animal studies, the nasal and oral
administration of Foralumab offers the potential for the
immunotherapy of autoimmune and inflammatory diseases in a safe
manner by the induction of Tregs.
About Tiziana Life
SciencesTiziana Life Sciences plc is a dual listed
(NASDAQ:TLSA, UK LSE: TILS) biotechnology company that focuses on
the discovery and development of novel molecules to treat human
diseases in oncology, inflammation and infectious diseases. In
addition to Milciclib, the Company will be shortly initiating Phase
2 studies with orally administered Foralumab for Crohn's Disease
and nasally administered Foralumab for progressive multiple
sclerosis. Foralumab is the only fully human anti-CD3 monoclonal
antibody ("mAb") in clinical development in the world. This Phase 2
compound has potential application in a wide range of autoimmune
and inflammatory diseases, such as Crohn's Disease, multiple
sclerosis, type-1 diabetes ("T1D"), inflammatory bowel disease
("IBD"), psoriasis and rheumatoid arthritis, where modulation of a
T-cell response is desirable. The Company is accelerating
development of anti-Interleukin 6 receptor ("IL6R") mAb, a fully
human monoclonal antibody for treatment of IL6-induced
inflammation, especially for treatment of COVID-19 patients.
Forward-Looking Statements
Certain statements made in this announcement are
forward-looking statements. These forward-looking statements are
not historical facts but rather are based on the Company's current
expectations, estimates, and projections about its industry; its
beliefs; and assumptions. Words such as 'anticipates,' 'expects,'
'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar
expressions are intended to identify forward-looking statements.
These statements are not guarantees of future performance and are
subject to known and unknown risks, uncertainties, and other
factors, some of which are beyond the Company's control, are
difficult to predict, and could cause actual results to differ
materially from those expressed or forecasted in the
forward-looking statements. The Company cautions security holders
and prospective security holders not to place undue reliance on
these forward-looking statements, which reflect the view of the
Company only as of the date of this announcement. The
forward-looking statements made in this announcement relate only to
events as of the date on which the statements are made. The Company
will not undertake any obligation to release publicly any revisions
or updates to these forward-looking statements to reflect events,
circumstances, or unanticipated events occurring after the date of
this announcement except as required by law or by any appropriate
regulatory authority.
For further enquiries: |
|
United Kingdom: |
|
Tiziana Life Sciences plc |
+44 (0)20 7495 2379 |
Gabriele Cerrone,
Chairman, and founder |
|
|
United
States: |
Investors: |
Dave Gentry,
CEO |
RedChip Companies
Inc. |
407-491-4498 |
dave@redchip.com |
Tiziana Life Sciences (NASDAQ:TLSA)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Tiziana Life Sciences (NASDAQ:TLSA)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024